Results 31 to 40 of about 42,464 (273)

Sildenafil-evoked photoreceptor oxidative stress in vivo is unrelated to impaired visual performance in mice.

PLoS ONE, 2021
PurposeThe phosphodiesterase inhibitor sildenafil is a promising treatment for neurodegenerative disease, but it can cause oxidative stress in photoreceptors ex vivo and degrade visual performance in humans.
Bruce A Berkowitz, Robert H Podolsky, Karen Lins Childers, Aicha Saadane, Timothy S Kern, Robin Roberts, Hailey Olds, Joydip Joy, Collin Richards, Tilman Rosales, Michael Schneider, Brennan Schilling, Arthur Orchanian, Emma Graffice, Kenan Sinan, Haohua Qian, Lamis Harp   +16 more
doaj   +1 more source

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

New England Journal of Medicine, 2018
Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion ...
M. Kolb, G. Raghu, A. Wells, J. Behr, L. Richeldi, B. Schinzel, M. Quaresma, S. Stowasser, F. Martinez   +8 more
semanticscholar   +1 more source

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants

Clinical pharmacology and therapy, 2020
Physiologically‐based pharmacokinetic (PBPK) modeling can potentially predict pediatric drug‐drug interactions (DDIs) when clinical DDI data are limited.
Sara N Salerno, A. Edginton, Jacqueline G. Gerhart, M. Laughon, N. Ambalavanan, G. Sokol, C. Hornik, D. Stewart, Mary Mills, K. Martz, Daniel Gonzalez   +10 more
semanticscholar   +1 more source

Placental effects and transfer of sildenafil in healthy and preeclamptic conditionsResearch in context

EBioMedicine, 2019
Background: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a promising treatment for preeclampsia (PE). However, a sildenafil trial was recently halted due to lack of effect and increased neonatal morbidity.
Emilie Hitzerd, Michelle Broekhuizen, Katrina M. Mirabito Colafella, Marija Glisic, René de Vries, Birgit C.P. Koch, Michiel A. de Raaf, Daphne Merkus, Sam Schoenmakers, Irwin K.M. Reiss, A.H. Jan Danser, Sinno H.P. Simons   +11 more
doaj   +1 more source

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor

Infectious Disease Reports, 2015
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli, Maria P. Cicini, Leopoldo P. Pucillo, Nicola Petrosillo   +7 more
doaj   +1 more source

Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review

BMJ Open Sport & Exercise Medicine, 2019
Objective Sildenafil is a pulmonary vasodilator that may reduce the decrement in endurance performance in moderate hypoxia. We assessed the efficacy of sildenafil to improve performance in hypoxia.Data sources/eligibility Criteria We systematically ...
Eric Alexander Carter, Keith Lohse, William Sheel, Michael Koehle   +3 more
doaj   +1 more source

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis

Scientific Reports, 2021
Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF).
Jieun Kang, Jin Woo Song
doaj   +1 more source

Acute effect of sildenafil on myocardial ischemic territories in patients with stable coronary artery disease

The Egyptian Heart Journal, 2014
Objectives: To test the safety of sildenafil in patients with stable coronary artery disease (CAD). Methods: Sixty-one patients with stable CAD, documented by coronary angiography were included in this phase I study.
Mohamed Salem, Ahmed Bendary, Shaimaa Moustafa, Ahmed Ramzy, Osama Sanad   +4 more
doaj   +1 more source

Sildenafil citrate effects on seminal parameters in male participants with idiopathic infertility; A randomized, double-blind, controlled cross-over clinical trial study

Urological Science, 2022
Purpose: Sildenafil is a phosphodiesterase Type 5 inhibitor, which is a powerful and effective therapy for male erectile dysfunction (ED) and enables to restore temporary ED.
Gholamreza Mokhtari, Ali Hamidi Madani, Ehsan Kazemnezhad Leyli, Alireza Jafari   +3 more
doaj   +1 more source

STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early‐onset fetal growth restriction

BJOG: an International Journal of Obstetrics and Gynaecology, 2019
To assess the effect of maternal sildenafil therapy on fetal growth in pregnancies with early‐onset fetal growth restriction.
K. Groom, K. Groom, L. Mccowan, L. Mccowan, L. Mackay, Arier C. Lee, G. Gardener, J. Unterscheider, J. Unterscheider, R. Sekar, J. Dickinson, J. Dickinson, Peter Muller, R. Reid, D. Watson, A. Welsh, A. Welsh, Jay Marlow, S. Walker, S. Walker, J. Hyett, J. Hyett, J. Morris, P. Stone, P. Baker, P. Baker   +25 more
semanticscholar   +1 more source